The tool "Dormicum" describes the instruction as a
sleeping pill, which is part of the group of benzodiazepine derivatives. The use of this medication has a pronounced anxiolytic, muscle relaxant, sedative and anticonvulsant effect on the human body. The Dormicum medication (the instruction confirms this) accelerates the onset of sleep, significantly increases its duration, and at the same time does not have any negative effect on the phase of so-called REM sleep.
This sedative is available in the form of tablets and as a solution for injection. The composition of these dosage forms as an active ingredient includes midazolam. In tablets, it is contained in a volume of fifteen milligrams, and in solution - in a volume of five milligrams.
Dormicum prescribes anxiolytic capsules "Dormicum", mainly for the treatment of people suffering from insomnia or any other disorders associated with falling asleep and early awakening. In addition, specialists actively use this
sedative in combination with ketamine for ataralgesia in young patients. During premedication before a variety of surgical and diagnostic procedures, the use of the muscle relaxant Dormicum is also indicated. Tablets are recommended for long-term sedation. In addition, this anticonvulsant is administered intravenously as anesthesia during inhalation-type anesthesia.
To prescribe anxiolytic tablets "Dormicum" the instruction strictly does not recommend to people with individual intolerance to midazolam, as well as to all those who suffer from severe myasthenia gravis. In case of a sleep disorder provoked by severe forms of depression or psychosis, you should also refrain from using this muscle relaxant medicine. In addition, contraindications are pregnancy (especially the first trimester), childhood and breastfeeding. In the latter case, lactation should be completely stopped during treatment. With extreme caution, the
anticonvulsant drug Dormicum is prescribed if the patient has heart failure, organic brain damage, respiratory or liver failure, and also sleep apnea. In addition, this sedative should be administered only under medical supervision to women during the second or third trimester of pregnancy.
If we talk about possible adverse reactions provoked by the use of the anxiolytic drug “Dormicum”, then first of all it is necessary to distinguish such conditions as bradycardia, laryngospasm, respiratory depression, headache, hallucinations, vomiting, nausea, hiccups, drowsiness, shortness of breath and ataxia. In addition, some patients complain of apnea, high blood pressure, cramps, skin rash, and urticaria. There is also a risk of developing anterograde amnesia and excessive sedation.